DemeRx Strengthens Leadership Team With Appointment of Biopharmaceutical Executive Michael Snitkovsky as Chief Operations Officer
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from preclinical research through clinical development. Mr. Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and global teams around shared scientific and business objectives—capabilities that support effective risk management, development acceleration, and long‑term value creation.
DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for DMX-1001 (oral noribogaine), a novel neuroplastogen therapeutic for the treatment of alcohol use disorder (AUD).
DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced positive results from its Phase 1 multiple ascending dose (MAD) study of DMX-1001 (oral noribogaine) for the treatment of alcohol use disorder (AUD). The results demonstrated safety, tolerability, and pharmacokinetics that support advancing DMX-1001 to Phase 2 clinical trials in people with AUD.
DemeRx Awarded $1.7 Million National Institutes of Health Grant to Advance Potential First-in-Class Neuroplastogen Drug Candidate DMX-1001 for Alcohol Use Disorder (AUD)
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced it was awarded a $1.7 million Small Business Innovation Research (SBIR) Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH). This funding will help advance DemeRx's promising neuroplastogen drug candidate, DMX-1001 (noribogaine), through the necessary IND-enabling studies and toward Phase 2 clinical trials for the treatment of Alcohol Use Disorder (AUD).
